Today, we announced an exciting addition to UCB’s epilepsy pipeline with an agreement to acquire the rights to Proximagen’s Midazolam Nasal Spray (USL261),¹ an anti-epilepsy drug (AED) developed as an intended rescue treatment for acute repetitive seizures (ARS, also known as serial, recurrent or cluster seizures) in patients with epilepsy.

UCB to expand epilepsy portfolio with strategic acquisition of Midazolam Nasal Spray from Proximagen

April is Parkinson’s Awareness Month. To honor those living with Parkinson’s disease (PD), we’re spreading awareness about the disease and sharing some of our favorite stories of inspiration.

As the U.S. affiliate of UCB, a global biopharmaceutical company, we are excited to be relaunching UCB-USA.com and a blog with news on UCB in the U.S.

UCBCares^® is UCB, Inc.'s single source solution center in the U.S. dedicated to providing exceptional caring experiences and solutions for all incoming inquiries to UCB from patients, caregivers, and healthcare providers.

UCB strengthens research capabilities with acquisition of Element Genomics, a Duke University biotech spin-off

CIMZIA® (certolizumab pegol) label update marks major advance for women of childbearing age with chronic inflammatory disease in the U.S.

UCB is dedicated to supporting STEM education in the communities where we work and live. As part of this commitment, UCB is a proud sponsor of the new special exhibit, “The Secret World Inside You,” at Atlanta’s Fernbank Museum of Natural History.

UCB Advances Psoriasis Pipeline with Positive Data at American Academy of Dermatology Annual Meeting (AAD 2018).

Last year, UCB was invited to become a member of the Association of Military Surgeons of the United States (AMSUS) Executive Advisory Board as the only pharmaceutical industry representative.